HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance
Circulation · 19.05.2026 · 153 (20) · 1549-1568
DOI: 10.1161/circulationaha.125.076423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 19.05.2026. Verfasst von Yanjia Che und 19 weiteren Autor:innen. Beteiligte Einrichtung: Transplantation Research Center (Y.C., Y.Y., S.J., G.S., S.M.K., H.B., X.L., A.J.S., M.Y., Y.I., J.Z., V.K., R.A.), Boston, MA. Hauptthemen laut MEDLINE: Heart Transplantation, Immunoconjugates, Graft Rejection, Graft Survival. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: The entrance of naive T cells into lymph nodes (LNs) is a crucial step for induction of heart transplant acceptance under costimulatory blockade. Specialized blood vessels within the LN known as high endothelial venules (HEVs) mediate this process. HEVs express a key glycoprotein containing 6-sulfo sialyl Lewis X, the binding site for L-selectin on the membrane of naive T cells. The proper formation of this carbohydrate requires sulfation by N-acetylglucosamine 6-O-sulfotransferases, particularly CHST4. Given the critical role of CHST4 in HEVs and transplant immunity, we aimed to develop a first-in-class antibody-drug conjugate (ADC) targeting the CHST4/HEV axis to deliver immunoregulatory therapeutics to LNs and promote long-term cardiac transplant survival. METHODS: We used CHST4 knockout mice and inducible diphtheria toxin receptor mouse models to investigate the role of CHST4 in HEV function during heart allograft transplantation. To assess the impact of CHST4 deficiency on heart transplant outcomes, we used fully major histocompatibility complex–mismatched and single major histocompatibility complex class II–mismatched models to study acute and chronic heart transplant rejection, respectively. We developed a first-in-class, dual-payload antibody-drug conjugate aimed at promoting regulatory T cells by conjugating rapamycin and tubastatin A to the HEV-targeting MHA112 antibody. The efficacy of this ADC was tested in murine heart allograft models. RESULTS: Loss of CHST4 expression by HEVs impaired the entry of naive T cells into LNs and consequently reduced regulatory T cell formation, thereby disrupting cardiac transplant acceptance under costimulatory blockade. Treatment with the HEV-targeted ADC carrying rapamycin and tubastatin A prolonged murine heart allograft survival and suppressed chronic rejection, a major barrier to long-term graft success. Mechanistically, this ADC enhanced regulatory T cell induction, reduced proinflammatory T cells within lymph nodes, and decreased immune cell infiltration in cardiac allografts, achieving these effects with substantially lower doses of rapamycin and tubastatin A compared with administration of the free drugs. CONCLUSIONS: Our findings uncover a key mechanistic role for CHST4 in HEVs in facilitating the regulatory T cell generation within the LN and promoting heart transplant acceptance. Moreover, we introduce a promising CHST4-based, HEV-targeted ADC therapy as a potential strategy to suppress heart transplant rejection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transplantation Research Center (Y.C., Y.Y., S.J., G.S., S.M.K., H.B., X.L., A.J.S., M.Y., Y.I., J.Z., V.K., R.A.), Boston, MA.
- Renal Division, Brigham and Women's Hospital, Harvard Medical School (Y.C., Y.Y., S.J., G.S., S.M.K., H.B., X.L., A.J.S., M.Y., Y.I., J.Z., V.K.), Boston, MA.
- Department of Nephrology and Rheumatology, Kanazawa University, Japan (Y.Y.).
- Graduate School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea (S.E.L., P.K.).
- KAIST Institute for Health Science and Technology, Daejeon, Republic of Korea (S.E.L., P.K.).
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore (Y.S.).
ORCID-Profile: Yuta Yamamura, Shameer M Kondengadan, Stephani Edwina Lucia, Yang Song, Hayeon Byun, Andy J Seelam, Jing Zhao, Joren C Madsen, Kenji Uchimura, George C Tsokos, Jonathan S Bromberg
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Che, Y., Yamamura, Y., Jung, S., Sabiu, G., Kondengadan, S. M., Lucia, S. E., Song, Y., Byun, H., Li, X., Seelam, A. J., Yamamura, M., Inoue, Y., Zhao, J., Madsen, J. C., Kasinath, V., Uchimura, K., Tsokos, G. C., Kim, P., Bromberg, J. S., & Abdi, R. (2026). HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance. Circulation, 153(20), 1549-1568. https://doi.org/10.1161/circulationaha.125.076423
Vancouver
Che Y, Yamamura Y, Jung S, Sabiu G, Kondengadan SM, Lucia SE, et al. HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance. Circulation. 2026;153(20):1549-1568. doi:10.1161/circulationaha.125.076423
BibTeX
@article{Che2026,
author = {Che, Yanjia and Yamamura, Yuta and Jung, Sungwook and Sabiu, Gianmarco and Kondengadan, Shameer M and Lucia, Stephani Edwina and Song, Yang and Byun, Hayeon and Li, Xiaofei and Seelam, Andy J and Yamamura, Minako and Inoue, Yuta and Zhao, Jing and Madsen, Joren C and Kasinath, Vivek and Uchimura, Kenji and Tsokos, George C and Kim, Pilhan and Bromberg, Jonathan S and Abdi, Reza},
title = {HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance},
journal = {Circulation},
year = {2026},
volume = {153},
number = {20},
pages = {1549--1568},
doi = {10.1161/circulationaha.125.076423}
}
EUVIMED